Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02352402
Other study ID # POPCABG
Secondary ID 2014-002142-50
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date March 2015
Est. completion date August 2020

Study information

Verified date April 2020
Source St. Antonius Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the POPular CABG study we investigate if the addition of ticagrelor, a drug that inhibits blood platelets from clotting, to treatment with aspirin will reduce the rate of saphenous vein graft occlusion as assessed with coronary computed tomography angiography at 1 year after coronary artery bypass grafting surgery.


Description:

Rationale: Acetylsalicylic acid (ASA) is used to prevent the occlusion of grafts placed during coronary artery bypass grafting surgery (CABG) and to reduce the incidence of atherothrombotic events during follow-up. Graft occlusion occurs predominantly in saphenous vein grafts (SVGs) and can result in symptoms of chest pain, myocardial infarction (MI) and even death. The anti-thrombotic effect of ASA is a result of the inhibition of the generation of thromboxane A2 (TXA2) in blood platelets. Despite ASA therapy, 6.8% to 26% of SVGs occlude in the first year after CABG, mainly due to thrombus formation. This might be due to the fact that ASA is not equally effective in all patients, indicated by a substantial amount of patients that still generate TXA2 and show activated platelets, despite adequate ASA use. We hypothesize that more potent platelet inhibition by the addition of ticagrelor to standard ASA therapy could decrease the rate of SVG occlusion.

Main objective: To investigate whether a combination of ticagrelor 90mg twice daily and ASA 80mg once daily is superior to ASA 80mg once daily alone in the prevention of SVG occlusion in patients who underwent CABG with use of one or more SVGs, as assessed with coronary computed tomography angiography (CCTA) at 1 year after randomization.

Study design: Randomized, double-blind, placebo-controlled, multicenter trial. Number of patients: Approximately 500 patients will be randomized.

Study population: Patients undergoing CABG with one or more SVGs, CABG being an isolated procedure or part of combined surgery.

Informed consent procedure, screening and sample size: We will screen patients and obtain informed consent before CABG. After CABG patients who gave informed consent are screened again to check if the patient fulfills the inclusion criteria and does not have any exclusion criteria. A total of 500 patients will receive randomized study medication after CABG.

Intervention: Patients will be randomly assigned to treatment with 90mg of ticagrelor or a matching placebo twice daily in addition to standard treatment with ASA for the duration of 1 year. Patients will be prescribed 80mg of ASA once daily according to routine clinical practice. Graft patency will be assessed with CCTA 1 year after randomization. If the patient consents to participate in the substudies, platelet function tests will be performed before surgery and 3 days and 1 year after randomization. Thirty day and one-year follow-up of clinical events will be obtained for all patients by screening the (electronic) patient file, telephonic interviews, study site visits and possibly with questionnaires.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 487
Est. completion date August 2020
Est. primary completion date August 2020
Accepts healthy volunteers No
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria:

- More than 21 years of age

- Planned coronary artery bypass grafting (CABG) with the use of 1 or more saphenous vein grafts, CABG being an isolated procedure or part of a combined aortic valce replacement surgery with bioprothesis.

Exclusion Criteria:

- Unable to give informed consent or a life expectancy of less than 1 year

- Concomitant valve, aorta or rhythm surgery during the same session, (excluding aortic bioprothesis)

- Inability to undergo coronary computed tomography angiography, in the investigator's opinion, for instance due to severe claustrophobia or contrast allergy

- Use of oral anticoagulants (acenocoumarol, phenprocoumon, dabigatran, rivaroxaban, etc) and a contraindication for discontinuation of this medication or the expectation that the patient will have an indication for the use of these drugs after surgery

- Placement of a drug-eluting stent in a coronary or cerebral artery within 6 months of CABG or placement of a bare-metal stent in a coronary or cerebral artery within 1 month of CABG

- Use of antiplatelet drugs other than aspirin (clopidogrel, prasugrel, ticagrelor, dipyridamol, etc.) and a contraindication for discontinuation of this medication after CABG, according to the treating physician or the investigator

- Women who are known to be pregnant, who have given birth within the past 90 days or who are breastfeeding

- Pre-menopausal women without adequate contraception

- Severe renal function impairment requiring dialysis

- Moderate or severe hepatic impairment

- Active malignancy with increase in bleeding risk, in the investigator's opinion

- Use of strong inhibitors of CYP3A4 (e.g. ketaconazole, clarithromycin, nefazodone, ritonavir, atazanavir)

- Clinically significant out of range values for platelet count or haemoglobin at screening, in the investigator's opinion

- Contraindication for the use of ticagrelor or aspirin (i.e. history of intracranial bleeding, high bleeding risk, previous allergic reaction), in the investigator's opinion

- Previous inclusion in this study

Study Design


Intervention

Drug:
Ticagrelor

Placebo


Locations

Country Name City State
Netherlands Catharina Ziekenhuis Eindhoven
Netherlands Medisch Spectrum Twente Enschede
Netherlands Universitair Medisch Centrum Groningen Groningen
Netherlands St Antonius Hospital Nieuwegein Utrecht
Netherlands Radboud UMC Nijmegen
Netherlands Erasmus Erasmus UMC Rotterdam

Sponsors (2)

Lead Sponsor Collaborator
J.M. ten Berg AstraZeneca

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Willemsen LM, Janssen PWA, Hackeng CM, Kelder JC, Tijssen JGP, van Straten AHM, Soliman-Hamad MA, Deneer VHM, Daeter EJ, Sonker U, Klein P, Ten Berg JM. A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial. Am Heart J. 2020 Feb;220:237-245. doi: 10.1016/j.ahj.2019.12.001. Epub 2019 Dec 13. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Saphenous vein graft occlusion As assessed with coronary computed tomography angiography or clinically indicated coronary angiography 1 year after coronary artery bypass grafting
Secondary Saphenous vein graft failure Composite of saphenous vein graft occlusion as assessed with coronary computed tomography angiography or clinically indicated coronary angiography, saphenous vein graft revascularization, myocardial infarction in the myocardial territory supplied by a saphenous vein graft or sudden death 1 year after coronary artery bypass grafting
Secondary Significant saphenous vein graft stenosis As assessed with coronary computed tomography angiography or clinically indicated coronary angiography 1 year after coronary artery bypass grafting
Secondary BARC minor (type 1 or 2) and major (type 3, 4 or 5) bleeding Bleeding Academic Research Consortium bleeding criteria 30 days after coronary artery bypass grafting
Secondary BARC minor (type 1 or 2) and major (type 3, 4 or 5) bleeding Bleeding Academic Research Consortium bleeding criteria 1 year after coronary artery bypass grafting
Secondary TIMI minor and major bleeding Thrombolysis in Myocardial Infarction bleeding criteria 30 days after coronary artery bypass grafting
Secondary TIMI minor and major bleeding Thrombolysis in Myocardial Infarction bleeding criteria 1 year after coronary artery bypass grafting
Secondary High platelet reactivity As assessed with platelet function tests. Within 72h before coronary artery bypass grafting
Secondary High platelet reactivity As assessed with platelet function tests. 3 days after coronary artery bypass grafting
Secondary High platelet reactivity As assessed with platelet function tests. 1 year after coronary artery bypass grafting
Secondary Level of GDF-15 Growth differentiation factor 15 level Within 72h before coronary artery bypass grafting
Secondary Level of GDF-15 Growth differentiation factor 15 level 3 days after coronary artery bypass grafting
Secondary Level of GDF-15 Growth differentiation factor 15 level 1 year after coronary artery bypass grafting
Secondary Arterial graft occlusion As assessed with coronary computed tomography angiography or clinically indicated coronary angiography 1 year after coronary artery bypass grafting
Secondary All graft occlusion As assessed with coronary computed tomography angiography or clinically indicated coronary angiography 1 year after coronary artery bypass grafting
Secondary Significant arterial graft stenosis As assessed with coronary computed tomography angiography or clinically indicated coronary angiography 1 year after coronary artery bypass grafting
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A